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Summary
Background Patients with psoriasis and clinicians are concerned that infliximab may
be associated with a risk of serious infections.
Objectives To compare the risk of serious infections associated with infliximab in
patients with chronic plaque psoriasis against a cohort on nonbiologic systemic
therapies.
Methods A prospective cohort study was performed using data from the British
Association of Dermatologists Biologic Interventions Register (BADBIR). Inflix-
imab was compared with nonbiologic systemic therapies, inclusive of any
exposure to methotrexate, ciclosporin, acitretin, fumaric acid esters, psoralen-
ultraviolet A or hydroxycarbamide. Serious infections were those associated with
hospitalization, the use of intravenous antimicrobial therapy and/or those that
led to death. Propensity score inverse probability treatment weights were used to
adjust for potential confounding from a priori identified covariates. Cox
proportional hazards models were calculated to obtain hazard ratios (HRs).
Results In total, 3843 participants were included for analysis up to October 2016.
The incidence rates were significantly higher in the infliximab cohort (478 per
1000 person-years) [95% confidence interval (CI) 357–640], compared with
142 per 1000 person-years (95% CI 115–174) in the nonbiologic systemic
cohort. Infliximab was associated with an overall increase in the risk of serious
infection compared with nonbiologics [adjusted HR (adjHR) 195, 95% CI 101–
375] and methotrexate only (adjHR 296, 95% CI 158–557) and a higher risk
of serious infection in the first 6 months of therapy (adjHR 349, 95% CI 114–
1070).
Conclusions Infliximab is associated with an increased risk of serious infections
compared with nonbiologic systemic therapies in patients with psoriasis in the
U.K. and the Republic of Ireland.
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What’s already known about this topic?
• Randomized clinical trials are not sufficiently powered to investigate the risk of
serious infection in patients with psoriasis who are undergoing treatment with
infliximab.
• Published observational studies have used different methods to adjust for con-
founding and different comparators.
• Previous studies also lacked the adequate sample size to obtain a precise estimate of
the risk of serious infection for infliximab.
What does this study add?
• Using methods that better address bias and confounding, our study suggests that
infliximab is associated with a higher risk of serious infections compared with
nonbiologic systemic therapies in patients with psoriasis.
• Patients should be counselled on the risk of serious infection before infliximab is
prescribed.
Infliximab, a chimeric monoclonal antibody against tumour
necrosis factor-a, is highly efficacious for the treatment of psori-
asis.1 In the U.K., infliximab use for psoriasis is reserved for
patients with very severe disease, i.e. with a Psoriasis Area and
Severity Index (PASI) ≥ 20 and Dermatology Life Quality Index
(DLQI) > 18, compared with other biologic therapies where the
disease severity criteria are lower, i.e. PASI ≥ 10, DLQI > 10.
The British Association of Dermatologists guidelines for biologic
therapies in psoriasis specifically recommend that infliximab is
reserved for people with very severe disease or where other
available biologic agents have failed or cannot be used.2 By indi-
cation, patients treated with infliximab are therefore substan-
tially different to those treated with other biologic therapies.
One of the main adverse events leading to discontinuation of
biologic therapies is infection.3 Serious infections, which are
defined as those associated with significant morbidity or mortal-
ity, are therefore a legitimate concern for clinicians and patients.
Most of the evidence for the quantification of the risk of serious
infection in patients with psoriasis on infliximab is drawn from
data in randomized clinical trials (RCTs) with important limita-
tions including poor external validity,4 low event rates and
unclear reporting of outcome.5 A systematic review of RCTs
found that infliximab was associated with a nonstatistically sig-
nificant increase in the risk of serious infection compared with
placebo at weeks 20–30 [Peto odds ratio 353, 95% confidence
interval (CI) 031–4037].5 Two prospective observational
cohort studies have reported on the risk of serious infection
with infliximab in patients with psoriasis; one study with 184
patients (2642 person-years) on infliximab showed nonstatisti-
cally significant increased risk with infliximab compared with
methotrexate,6 while another study showed statistically signifi-
cant increased risk compared with retinoids/phototherapy in a
prevalent cohort (1151 patients, 2253 person-years) but not in
an incident cohort (246 patients, 324 person-years).7 Both
observational studies were limited by a small incident cohort of
patients on infliximab.
Our objective is to determine whether infliximab elevates
the risk of serious infection above that of nonbiologic sys-
temic therapies in patients with psoriasis, using a large,
national, prospective psoriasis registry – the British Association
of Dermatologists Biologic Interventions Register (BADBIR).
Patients and methods
BADBIR is a national prospective ongoing pharmacovigilance
registry of patients with psoriasis that was established in 2007
in the U.K. and Republic of Ireland to compare the safety of
biologic therapies vs. nonbiologic systemic therapies. Estab-
lishing the risk of serious infections was a prespecified pri-
mary aim of the registry. The design of BADBIR8 and the
baseline patient characteristics9 have been published previ-
ously. The National Institute for Health and Care Excellence
(NICE) recommends that all patients with psoriasis on biologic
therapies should be registered on BADBIR. Patients were
selected using a data snapshot from October 2016. BADBIR
was approved in March 2007 by the National Health Service
Research Ethics Committee North West England (07/MRE08/
9). All patients gave written informed consent for their partic-
ipation in the registry.
Baseline assessment
Baseline data were collected before or during the initial 6
months of treatment. Drug, clinical and comorbidity history
along with anthropometric data were collected by a healthcare
professional using a web-administered questionnaire, whereas
lifestyle factors were collected using a patient-completed
questionnaire.
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Follow-up assessments
Data from patients were collected every 6 months for the first
3 years, then annually thereafter up to 10 years. Follow-up
data were collected and entered into a web-based system con-
temporaneously. Specific information about serious infections
were collected, including descriptions of events, hospitaliza-
tion, start and stop dates. Adverse events were classified using
the Medical Dictionary for Regulatory Activities (MedDRA)
system.
Data analysis
The main inclusion criteria for this study were patients with
chronic plaque psoriasis starting infliximab (Remicade, John-
son & Johnson, New Brunswick, NJ, U.S.A.) and biologic-
na€ıve patients with chronic plaque psoriasis on acitretin,
psoralen-ultraviolet A, ciclosporin, fumaric acid esters,
methotrexate or hydroxycarbamide, who were recruited in the
nonbiologic systemic cohort. Owing to difficulties such as a
low sample size for infliximab and a lack of comparable
patients receiving other biologic therapies, adalimumab,
etanercept and ustekinumab were analysed separately.10 Analy-
sis of patients who were biologic-na€ıve (i.e. first-line inflix-
imab therapy) was performed separately to the aggregated
analysis with all patients in the infliximab cohort (i.e. all-lines
infliximab therapy).
Patients were included if follow-up data (at least one fol-
low-up) were available. Overall, 844 patients were not
included; three emigrated, 785 withdrew consent and 56 did
not complete their questionnaire. Patients on infliximab con-
tributed follow-up time from the first dose until the first
occurrence of the following events: serious infection, discon-
tinuation of treatment owing to other reasons, last registered
follow-up, switch to other biologic therapy or death. Patients
in the nonbiologic cohort contributed follow-up time from
first dose of the index drug until the first event of any of the
above, but were censored at the end of the last alternative
nonbiologic therapy. Patients who switched from the nonbio-
logic therapy cohort to start infliximab contributed follow-up
time to both cohorts.
A serious infection was defined as any infection that was asso-
ciated with or prolonged hospitalization, use of intravenous
antimicrobial therapy or led to death. The events were validated
by separate review from two clinicians (Z.Z.N.Y. and R.B.W.)
against the above criteria, and discrepancies were resolved
through discussion. A clinical specialist in the specific type of
infection was consulted in cases where there was uncertainty. The
first serious infection was included for analysis in the current
study, with a risk window period of 90 days following cessation
of treatment applied for the attribution of the event to the drug.11
The impact of alternate dosing regimens was not analysed
as the proportion of patients using cumulative doses that differ
from the licensed dosing regimens is low in the U.K.
(< 15%)12 and the NICE-approved dosing regimen is in accor-
dance with the licence. Within the infliximab cohort, the
number of person-years receiving doses outside the licence
was too low to make statistical inferences regarding the effect
of dosing regimen on the risk of serious infection.
Primary analyses
To provide a description of the rates of serious infections, crude
incidence rates for each drug in the biologic cohort and in the
nonbiologic cohort were calculated as the number of events per
1000 patient-years of follow-up. Survival modelling with Cox
proportional hazards was used to compare event rates and esti-
mate the effect of each exposure on the risk of serious infec-
tions. To investigate whether the risk of serious infections was
time varying, we used the crude incidence rates at 0–6 months,
6–12 months and 12–24 months of follow-up, which are the
designated follow-up data reporting time points.
The specific a priori potential confounders that were included in
the multivariable analysis were based on expert opinion and a lit-
erature review.5 These were age, sex, body mass index (BMI),
waist circumference, alcohol use, disease severity (PASI), con-
comitant inflammatory arthritis (including psoriatic arthritis and
ankylosing spondylitis), smoking, diabetes, chronic obstructive
pulmonary disease, asthma and concomitant immunosuppres-
sants. The total number of measured comorbidities was included
as a separate covariate as a proxy for patient frailty. BMI was pre-
sented as a categorical variable to ease data description in Table 1,
but was kept as a continuous variable in the statistical models.
Adjustment for the baseline potential confounders was performed
using a propensity score model. A probability score for having
the treatment was derived from a logistic regression model based
on the baseline relevant covariates listed above. The use of
propensity score adjustment has various advantages over multi-
variable regression models, in particular the ability to check the
balance of measured confounders between the comparator
cohorts, and improve estimation when an outcome is rare by
allowing for multiple covariates.13
Inverse probability treatment weighting, where the treat-
ments were weighted for the distribution of the propensity
score in the whole model cohort, was then performed using
propensity score probabilities in both models. Balance
between groups after weighting was assessed using expected
bias from a logistic regression model estimating the effect of
the variable on serious infection. Improvement in balance was
achieved by an iterative process of fitting interaction terms
involving the least balanced variables.
Concomitant therapies considered to be immunosuppres-
sants were methotrexate, ciclosporin, fumaric acid esters and
hydroxycarbamide. Concomitant immunosuppressants (defined
as the exposure period to more than one immunosuppressant
in the nonbiologic cohort) were treated exceptionally as time-
varying covariates, allowing for the time on and off these
drugs throughout follow-up.
Missing data (Table S1; see Supporting Information) were
imputed in a multiple imputation model of 20 datasets in
order to reduce bias.14 We used multiple imputations to
account for missing data for the potential confounders, as this
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preserves the variability and uncertainty of the missing data
and avoids loss of power and bias that alternative ad hoc
methods, such as a complete case analysis, may introduce.
Propensity likelihood scores were calculated in each imputed
dataset and combined after regression modelling using
Rubin’s rules. A key assumption for the Cox regression is the
proportionality assumption, where the relative risk between
the comparators is constant over time. Formal testing for pro-
portionality using Schoenfeld’s residuals in the Cox regression
model was performed in five extracted imputed datasets, and,
where the proportionality assumption did not hold, a time-
stratified analysis using the prespecified time points was
performed.
Secondary analyses
A priori planned sensitivity analysis included methotrexate users
as the comparator cohort as this was the most common sys-
temic nonbiologic in use. Descriptive analysis was performed
for soft tissue and skin infections and lower respiratory tract
infections as these were identified as common infections asso-
ciated with patients on biologic therapies, but the lower num-
ber of events did not allow for meaningful multivariable
analysis of relative risks (Table S2; see Supporting Informa-
tion).
All analyses were performed using Stata 14 (StataCorp LLC,
College Station, TX, U.S.A.). The methods used in this analysis
Table 1 The baseline demographic and disease characteristics of the infliximab and nonbiologic cohort
Characteristics
Nonbiologic cohort
(n = 3421)
First-line infliximab
(n = 105)
All-lines infliximab
(n = 422)
Age (years), mean  SD 446  140 466  135 466  127
Female sex 1489 (435) 32 (305) 159 (377)
Waist circumference (cm), mean  SD 997  171 1056  196 1061  187
BMI category (kg m2)
Underweight (< 185) 43 (13) 1 (10) 2 (05)
Normal (185–249) 677 (198) 19 (181) 54 (128)
Overweight (250–299) 1071 (313) 18 (171) 93 (220)
Obese I (300–349) 735 (215) 20 (190) 86 (204)
Obese II (350–399) 345 (101) 15 (143) 60 (142)
Obese III (≥ 40) 279 (82) 21 (200) 64 (152)
Comorbidities and risk factors
No comorbidity 1323 (387) 25 (238) 98 (232)
1–2 comorbidities 1585 (463) 48 (457) 197 (467)
3–4 comorbidities 416 (122) 23 (219) 92 (218)
≥ 5 comorbidities 97 (28) 9 (86) 35 (83)
Hypertension 620 (181) 35 (333) 142 (336)
Past TB 21 (06) 2 (19) 9 (21)
Diabetes mellitus 254 (74) 15 (143) 56 (133)
Dyslipidaemia 307 (90) 14 (133) 63 (149)
Asthma 361 (106) 9 (86) 54 (128)
COPD 69 (20) 1 (10) 7 (17)
Number of cigarettes smoked per day, mean  SD 46  77 59  88 48  95
Alcohol units per week, mean  SD 77  121 109  238 81 160
Disease
Disease duration (years), median (IQR) 180 (180) 190 (160) 206 (172)
Baseline PASI score, median (IQR) 141 (79) 246 (123) 203 (137)
Inflammatory arthritis 363 (106) 33 (314) 164 (389)
Treatment history
First-line biologic/nonbiologic therapy 3421 (1000) 105 (1000) 105 (249)
Second-line biologic therapy 131 (310)
Third-line biologic therapy 123 (291)
Fourth-line (or more) biologic therapy 63 (149)
Concomitant treatments
Any exposure to methotrexate during follow-up 2118 (619) 28 (267) 148 (351)
Any exposure to ciclosporin during follow-up 1216 (356) 6 (57) 43 (102)
Any exposure to fumaric acid esters during follow-up 552 (161) 2 (19) 7 (17)
Any exposure to hydroxycarbamide during follow-up 56 (16) 5 (48) 9 (21)
BMI, body mass index; PASI, Psoriasis Area and Severity Index. List of predefined comorbidities included hypertension, angina, myocardial
infarction, stroke, epilepsy, asthma, chronic obstructive pulmonary disease (COPD), peptic ulcer disease, chronic renal disease, liver disease,
previous tuberculosis (TB), demyelination, diabetes mellitus, impaired glucose tolerance, depression, dyslipidaemia, nonskin cancer, immun-
odeficiency syndromes and thyroid disease. Data are provided as n (%) unless otherwise stated.
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have been previously described.10 The details of the methodol-
ogy pertaining to this current study are reproduced in full for
the benefit of the reader.
Results
In total, 3843 participants were included in the analysis, with
3421 participants included in the nonbiologic systemic cohort
and 422 participants included in the all-lines infliximab cohort
up to October 2016. Overall, 105 biologic-na€ıve participants
were started on first-line infliximab therapy. The baseline
demographic, anthropometric and disease characteristics of the
participants are listed in Table 1. The total and median fol-
low-up time for all lines of infliximab was 9411 person-years
and 149 person-years [interquartile range (IQR) 250 person-
years], respectively. For biologic-na€ıve patients on infliximab
the total follow-up time was 23887 and the median follow-
up time was 184 person-years (IQR 270 person-years) and
for the nonbiologic cohort the total and median follow-up
time was 641924 person-years and 151 person-years (IQR
184 person-years), respectively.
Crude incidence rates for serious infections overall
The incidence rate for serious infections in the nonbiologic
cohort was 1418 per 1000 person-years (95% CI 1154–
1741), with the incidence rate for the methotrexate only
cohort at 1198 per 1000 person-years (95% CI 882–1627).
The crude incidence rate in the entire infliximab cohort was
4782 per 1000 person-years (95% CI 3570–6404), and
5861 per 1000 person-years (95% CI 3471–9896) for the
biologic-na€ıve infliximab cohort.
The most common serious infections coded using MedDRA
high level terms that were experienced by participants on
either nonbiologic systemic therapy or infliximab were lower
respiratory tract infections, followed by skin and soft tissue
infections and urinary tract infections (Table S2; see Support-
ing Information). The crude incidence rates for lower respira-
tory tract infections and skin and soft tissue infections were
higher for infliximab (Table 2). The median hospital inpatient
stay was 3 days (IQR 60) for nonbiologic therapies and 2
days for infliximab (IQR 90).
Propensity score weighted models for the risk of serious
infections
The inverse probability treatment weighted (IPTW) logistic
regression model for infliximab vs. nonbiologic therapies
achieved good balance, removing expected bias for most of the
variables (Fig. 1 and Table S3; see Supporting Information),
which suggested a reduction of confounding from these variables.
Infliximab showed a statistically significant increase in the
risk of serious infection compared with nonbiologic systemic
therapies overall [adjusted hazard ratio (HR) 195, 95% CI
101–375; Table 3]. The proportionality assumption was not
met for this model, and therefore a split in a priori defined fol-
low-up time was performed. The risk of serious infection was
significantly higher in the first 6 months (adjusted HR 349,
95% CI 114–1070) and between 6 months and 1 year (ad-
justed HR 299, 95% CI 110–814) but not significantly higher
between 1 and 2 years (adjusted HR 203, 95% CI 061–679)
compared with the nonbiologic cohort (Table 3). The adjusted
estimate for biologic-na€ıve participants on infliximab was also
higher than nonbiologic therapies but this was not statistically
significant (adjusted HR 137, 95% CI 050–374).
Sensitivity analysis
Infliximab (all lines) had a statistically significant increase in
the risk of serious infection compared with methotrexate
Table 2 Crude incidence rates of first serious infection overall (lower respiratory tract infections; skin and soft tissue infections)
Treatment n
Total person-time
(median follow-up time), years Infections Rate (per 1000 person-years) 95% CI (person-years)
All serious infections
Nonbiologics 3421 641924 (151) 91 1418 1154–1741
Methotrexate 2118 342240 (127) 41 1198 882–1627
Infliximab (first line) 105 23887 (184) 14 5861 3471–9896
Infliximab (all lines) 422 93522 (149) 45 4782 3570–6404
Lower respiratory tract infections
Nonbiologics 27 421 288–613
Methotrexate 14 409 242–691
Infliximab (first line) 105 <5 419 059–2972
Infliximab (all lines) 422 11 1169 647–2111
Skin and soft tissue infections
Nonbiologics 22 343 226–520
Methotrexate 10 292 157–543
Infliximab (first line) 105 5 2093 871–5029
Infliximab (all lines) 422 13 1381 802–2379
CI, confidence interval.
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(adjusted HR 296, 95% CI 158–557; Table 3). The propor-
tionality assumption was met for this alternative model.
Discussion
Infliximab was associated with a twofold increase in the risk
of serious infections compared with nonbiologic systemic
therapies, and a threefold increase in the risk of serious
infections compared with methotrexate, in patients with
psoriasis. This is in contrast to our results from other bio-
logic therapies in BADBIR, where etanercept, adalimumab
and ustekinumab were not associated with a higher risk of
serious infections than nonbiologic systemic therapies. There
was a time-stratified difference in the risk of serious infec-
tions in the comparison between infliximab and nonbiologic
therapies, with a higher risk in the first 6 months of ther-
apy and a lower risk after 1 year of therapy, but these esti-
mates had overlapping CIs given the fact that we had a
lower precision owing to a lack of power within the speci-
fic time strata.
We have shown that combination treatment of infliximab
with methotrexate, and other immunosuppressive therapies, is
associated with a threefold increase in the risk of serious
infection compared with patients on infliximab monotherapy
in the biologic-na€ıve cohort. This is not the case in the overall
cohort (i.e. both biologic-na€ıve and experienced) (Table 3).
However, the propensity score method balances the baseline
characteristics and not time-varying factors, and hence it can-
not deal adequately with confounding by indication for the
use of concomitant immunosuppressive therapy. Therefore,
this estimated result should be interpreted with caution.
The major strengths of this study are the prospective cohort
study design, fully industry-independent data analysis and the
participation of multiple dermatology centres (N = 153) in
the U.K. and Republic of Ireland. This study reports on the
risk of serious infection in the largest incident cohort of
patients with psoriasis on infliximab to date. Owing to the
capture of numerous important covariates, we were able to
account for significant confounding through weighting by
propensity score. The substantial reduction in the point esti-
mate of the HR after adjustment (> 40% change) suggests that
significant positive confounding was reduced after IPTW
propensity score adjustment.
Limitations include recall bias, which may occur with
patient-reported characteristics, and residual confounding
through variables that were not measured and not known to
be associated with either exposure or outcome. There is a
possibility that clinicians may have a lower threshold and a
heightened awareness for admitting patients on infliximab
with suspected infections compared with nonbiologic sys-
temic therapies, thereby introducing confounding by indica-
tion that cannot be adjusted for. As patients on infliximab
are by indication (higher PASI and DLQI) different from all
other patients on the registry, there may be a higher degree
Fig 1. Forest plot showing the reduction in expected percentage bias for the individual covariates after inverse probability treatment weighted
propensity score weighting.
PASI, Psoriasis Area and Severity Index; BMI, body mass index; COPD, chronic obstructive pulmonary disease.
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of selection bias in our comparisons. The potential con-
founding introduced by this selection bias may be partly
adjusted for from the measured covariates, and the propen-
sity score IPTW method reduced expected bias substantially
(Table S3; see Supporting Information), but there may be
unmeasured covariates that have introduced confounding that
cannot be adjusted for. For example, we were not able to
adjust for previous serious infection within the past year.
Conversely, our results have high external validity for
patients with psoriasis who are eligible for infliximab in the
U.K. or any other country with similar prescription eligibility
criteria for the drug. A total of 844 registered patients were
classified as dropping out owing to lack of follow-up. Of
these patients, 925% (785 patients) discontinued the study
owing to withdrawal of consent and, because the reason for
withdrawal is not provided, it is unclear how or whether
this would have introduced systematic bias.
We performed an analysis with an incident cohort, which
avoids left truncation. Left truncation occurs when there is a
period of time during which the event could have occurred
that cannot be observed. Involving a prevalent cohort would
introduce left truncation by selecting the involvement of
patients on infliximab who have not discontinued owing to
a serious infection, and selecting out those patients who
have discontinued infliximab owing to a serious infection,
thereby underestimating the associated risk in infliximab. To
maximize our sample size we included all lines of inflix-
imab therapy (i.e. biologic-experienced individuals who pro-
gressed onto infliximab as the second-line, third-line and
fourth-line biologic therapy); however, we also performed a
sensitivity analysis restricted to first-line infliximab therapy
in biologic-na€ıve participants. There is a possibility that
patients with severe psoriasis who experienced a serious
infection on the first-line biologic therapy are not subse-
quently prescribed infliximab. However, it is reassuring that
the results are contrary to this hypothesis, as the adjusted
results for infliximab involving all lines of therapy are
higher than those of first-line therapy with tighter CIs, sug-
gesting that the difference is due to sample size and power
rather than left truncation.
Our crude incidence rate for serious infections for inflix-
imab (478 per 1000 person-years) is higher than that pub-
lished in the Psoriasis Longitudinal Assessment and Registry
(PSOLAR), a large study based mainly in the U.S.A. and Eur-
ope sponsored by a single pharmaceutical company (inflix-
imab serious infection rate of 249 per 1000 person-years),7
and the Spanish Registry of Adverse Events from Biological
Therapy in Psoriasis (BIOBADADERM) (infliximab serious
infection rate of 189 per 1000 person-years).6 However, the
adjusted relative risks from these cohorts are broadly similar
to our results. PSOLAR reported an adjusted HR of 251 (95%
CI 145–433) in a mixed prevalent/incident population and
an adjusted HR of 178 in the incident population (95% CI
064–498), where the chosen comparator was a cohort on
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cohort where the chosen comparator was a cohort on
methotrexate only. The use of prevalent cohorts should be
avoided in the assessment of adverse events because of the risk
of left truncation, especially given the finding of an early high
risk of serious infections in the first 90 days of treatment for
infliximab in rheumatoid arthritis.11 Both PSOLAR and BIOBA-
DADERM incident cohorts did not have the requisite power to
achieve adequate estimate precision.
As discussed previously, infliximab is currently recom-
mended for patients with severe psoriasis only.2 A recent net-
work meta-analysis of evidence from clinical trials has found
infliximab to be of high efficacy but of poorer tolerability.1
Given our findings of a higher risk of serious infection associ-
ated with infliximab, we provide real-world evidence to rein-
force the position of infliximab in the psoriasis treatment
hierarchy. However, it should be noted that there is no real-
world evidence, as yet, for the risk of serious infection of
alternative, newer, licensed biologic therapies for psoriasis,
such as secukinumab or ixekizumab.
Infliximab is associated with an overall twofold increase in
the risk of serious infections when compared with nonbio-
logic systemic therapies. Patients with severe psoriasis who
fulfil the criteria for the prescription of infliximab should be
counselled for the risk of serious infection. These results are
relevant to patients in the U.K. and the Republic of Ireland,
and also in countries that have similar eligibility criteria for
the prescription of infliximab.
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